March 13, 2020
Company Name: AnGes Inc.
Presentative: Ei Yamada, President & CEO(Code Number 4563, Mothers of the TSE)
AnGes and Osaka University launch joint DNA vaccine development targeting novel
Coronavirus (COVID-19)-Participation of Daicel corporation with a new administration device technologyTokyo, March 13, 2020 - AnGes Inc. announced that Daicel Corporation (hereinafter “Daicel”), with a
new administration device technology to deliver drugs intracellularly, has decided to take part in ourproject with Osaka University in connection with the joint development of a DNA vaccine against a novelcoronavirus announced on March 5, 2020. Using the new jet injector Actranza™ lab during foradministration of a drug makes it possible to increase the efficiency of gene expression and to raise
antibody production capability of DNA vaccine, leading to the development of more efficient DNAvaccine. In this collaboration with Daicel to the joint development between AnGes and Osaka University,
the new drug administration device and Takarabio’s plasmid DNA production capability enable us to aim
to start clinical trial within 6 months.
【Daicel’s participation in the development of DNA vaccines targeting the novel coronavirus】
 Daicel is developing an intradermal gene transfer method, using this new administration device, andpromote research with Osaka University (Impulse Science for Medicine; Department of Health
Development and Medicine), aiming at its clinical application.
 Use of this new administration device is expected to increase the efficiency of intradermal genetic
expression and antibody production capability, enabling the development of more efficient DNA
vaccines.
【Overview of the development of preventive DNA vaccines against the novel coronavirus, using plasmid
DNA manufacturing technology-Reference information from the March 5 press release】
 Joint development of DNA vaccine against novel coronavirus between AnGes and Osaka University(Department of Clinical Gene Therapy; Department of Health Development and Medicine) based on
the previous achievement of plasmid DNA product.
 The manufacturing process can be established in a shorter period of time with the manufacture of
DNA vaccines, compared with the vaccine with using inactivated viruses (attenuated vaccines) or
the vaccine with using genetically modified virus protein.
 The manufacturing operations will be undertaken by Takara Bio Inc. that possesses manufacturing
technology and facilities of plasmid DNA.
<About Actranza™ lab, Daicel’s new drug administration device>
It is a technology driven by pyro combustion to deliver drug solutions inside a specific tissue without
using a needle. A study using animal models has reported that, compared to injections using theconventional needles, the device showed greater accuracy of the delivered sites, and increased theefficiency of gene expression. Because numerous immunocompetent cells exist intradermally compared
to intramuscularly, the device is expected to enhance vaccine efficiency.

<About DNA vaccine>
DNA vaccines are safe and can be produced in a short time period without using any dangerous
pathogens. By inoculating a circular DNA (plasmid) encoding the protein of the target pathogen, thepathogen protein is produced in the body and immunized against the pathogen. Unlike attenuatedvaccines, DNA vaccines are safe as they have no pathogenicity.
The impact this will have on the full-year consolidated results for this fiscal year is currently being
examined.
AnGes, Inc.
Public Relations & Investor Relations Group
Contact: https://www.anges.co.jp/en/contact/